CytomX Therapeutics Inc (CTMX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.71+0.82%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CTMX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||
| Revenues | 18.3 | 76.2 | 138.1 | 101.2 | 53.2 | 37.3 | 68.4 | 26.9 | 59.5 | 71.6 | 15.0 | 7.7 |
| Total Revenues | 18.3 | 76.2 | 138.1 | 101.2 | 53.2 | 37.3 | 68.4 | 26.9 | 59.5 | 71.6 | 15.0 | 7.7 |
| Operating Expenses & Income | ||||||||||||
| R&D Expenses | 73.4 | 68.7 | 83.4 | 77.7 | 111.6 | 114.2 | 112.9 | 131.6 | 103.9 | 92.3 | 54.8 | 28.4 |
| Operating Income | (87.2) | (22.4) | 25.0 | (6.5) | (101.3) | (116.0) | (80.5) | (141.5) | (77.9) | (46.3) | (59.6) | (33.2) |
| Earnings from Continuing Operations | ||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | 1.7 | 1.7 | 1.7 |
| Interest & Investment Income | 7.7 | 5.2 | 7.1 | 9.8 | 1.7 | 0.3 | 1.8 | 8.4 | 7.6 | 2.7 | 0.7 | 1.3 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | (0.9) | 1.0 | 0.4 |
| EBT, Incl. Unusual Items | (79.4) | (17.1) | 32.1 | 3.3 | (99.3) | (115.9) | (78.7) | (133.3) | (70.3) | (43.6) | (58.9) | (35.4) |
| Income Tax Expense | 0.2 | 0.2 | 0.2 | 3.9 | 0.0 | 0.0 | (13.9) | (0.4) | 14.3 | (0.5) | (0.0) | 0.0 |
| Net Income | ||||||||||||
| Net Income | (79.7) | (17.4) | 31.9 | (0.6) | (99.3) | (115.9) | (64.8) | (132.8) | (84.6) | (43.1) | (58.9) | (35.4) |
| Per Share | ||||||||||||
| Basic EPS | (0.36) | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.36) | — | — | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.08 | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 218.9 | 137.9 | 84.4 | 73.8 | 65.7 | 64.1 | 46.1 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 218.9 | 137.9 | 84.7 | 73.8 | 65.7 | 64.1 | 46.1 | — | — | — | — | — |
| Supplemental | ||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | (76.0) | (44.6) | (57.9) | (32.0) |
| EBIT | (87.2) | (22.4) | 25.0 | (6.5) | (101.3) | (116.0) | (80.5) | (141.5) | (77.9) | (46.3) | (59.6) | (33.2) |
| Effective Tax Rate | -0.3% | — | — | 117.1% | 0.0% | 0.0% | 17.7% | 0.3% | -20.3% | 1.2% | 0.0% | -0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.